Protopanaxatriol, a novel PPAR γ antagonist from Panax ginseng, alleviates steatosis in mice

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Zhang, Yu ^a   Yu, Lijing ^a   Cai, Wujie ^a   Fan, Shengjie ^a   Feng, Li ^a   Ji, Guang ^b   Huang, Cheng ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTOPANAXATRIOL; SAPOGENIN;

3T3 CELL LINE; ADIPOCYTE; ADIPOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ELECTRON TRANSPORT; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; LIPID DIET; LIVER; METABOLISM; MITOCHONDRION; MOUSE; OBESITY; PANAX; PATHOLOGY;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; CELL DIFFERENTIATION; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; LIVER; MICE; MITOCHONDRIA; OBESITY; PANAX; PPAR GAMMA; SAPOGENINS;

EID: 84923348924     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07375     Document Type: Article

References (47)

1. Kubota, N. et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4, 597-609 (1999).
2. Bugyi, B. From the history of the discovery of radioactivity (Henri Becquerel). Orvosi Hetilap 114, 3099-3100 (1973).
3. Cheng, Y. Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22, 3099-3108 (1973).
4. Blume, A. J., Dalton, C. & Sheppard, H. Adenosine-mediated elevation of cyclic 3':5'-adenosine monophosphate concentrations in cultured mouse neuroblastoma cells. Proc Natl Acad Sci USA 70, 3099-3102 (1973).
5. Yang, W. et al. The effects of periconceptional risk factor exposure and micronutrient supplementation on birth defects in Shaanxi Province in Western China. PLoS One 7, e53429 (2012).
6. Miles, P. D., Barak, Y., He, W., Evans, R. M. & Olefsky, J. M. Improved insulinsensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105, 287-292 (2000).
7. Yamauchi, T. et al Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108, 1001-1013 (2001).
8. Matsusue, K. et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111, 737-747 (2003).
9. Gong, Z. et al The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 150, 104-113 (2009).
10. Zhang, Y. et al Rhein Reduces Fat Weight in db/db Mouse and Prevents Diet-Induced Obesity in C57Bl/6 Mouse through the Inhibition of PPARgamma Signaling. PPAR Res 2012, 374936 (2012).
11. Goto, T., Kim, Y. I., Takahashi, N. & Kawada, T. Natural compounds regulate energy metabolism by the modulating the activity of lipid-sensing nuclear receptors. Mol Nutr Food Res 57, 20-33 (2013).
12. Browning, J. D. et al Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395 (2004).
13. Yki-Jarvinen, H. Fat in the liver and insulin resistance. Ann Med 37, 347-356 (2005).
14. Milic, S. & Stimac, D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 30, 158-162 (2012).
15. Yu, S. et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 278, 498-505 (2003).
16. Uno, K. et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 312, 1656-1659 (2006).
17. Inoue, M. et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 336, 215-222 (2005).
18. Rull, A. et al. Rosiglitazone and Fenofibrate Exacerbate Liver Steatosis in aMouse Model of Obesity and Hyperlipidemia. A Transcriptomic and Metabolomic Study. J Proteome Res, (2014).
19. Garcia-Ruiz, I. et al. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology 46, 414-423 (2007).
20. Gavrilova, O. et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278, 34268-34276 (2003).
21. Moran-Salvador, E. et al. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte-and macrophage-specific conditional knockouts. FASEB J 25, 2538-2550 (2011).
22. Jeon, W. J., Oh, J. S., Park, M. S. & Ji, G. E. Anti-hyperglycemic effect of fermented ginseng in type 2 diabetes mellitus mouse model. Phytother Res 27, 166-172 (2013).
23. Attele, A. S. et al. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 51, 1851-1858 (2002).
24. Liu, Z. et al. Antidiabetic effects of malonyl ginsenosides from Panax ginseng on type 2 diabetic rats induced by high-fat diet and streptozotocin. J Ethnopharmacol 145, 233-240 (2013).
25. Cho, W. C. et al. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol 550, 173-179 (2006).
26. Sotaniemi, E. A., Haapakoski, E. & Rautio, A. Ginseng therapy in non-insulindependent diabetic patients. Diabetes Care 18, 1373-1375 (1995).
27. Lee, M. R. et al. Anti-obesity effects of black ginseng extract in high fat diet-fed mice. J Ginseng Res 37, 308-349 (2013).
28. Gu, W., Kim, K. A. & Kim, D. H. Ginsenoside Rh1 ameliorates high fat dietinduced obesity in mice by inhibiting adipocyte differentiation. Biol Pharm Bull 36, 102-107 (2013).
29. Lee, H., Park, D. Yoon, M. Korean red ginseng (Panax ginseng) prevents obesity by inhibiting angiogenesis in high fat diet-induced obese C57BL/6J mice. Food Chem Toxicol 53, 402-408 (2013).
30. Hwang, J. T. et al. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother Res 23, 262-266 (2009).
31. Qi, L.W. et al. Metabolism of ginseng and its interactions with drugs. Curr Drug Metab 12, 818-822 (2011).
32. Korivi, M. et al. Ginsenoside-Rg1 Protects the Liver against Exhaustive Exercise-Induced Oxidative Stress in Rats. Evid Based Complement Alternat Med 2012, 932165 (2012).
33. Rangwala, S. M. & Lazar, M. A. Transcriptional control of adipogenesis. Annu Rev Nutr 20, 535-559 (2000).
34. Rosen, E. D. & Spiegelman, B. M. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 16, 145-171 (2000).
35. Schinner, S., Scherbaum, W. A., Bornstein, S. R. & Barthel, A. Molecular mechanisms of insulin resistance. Diabet Med 22, 674-682 (2005).
36. Koyama, K., Chen, G., Lee, Y. & Unger, R. H. Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Physiol 273, E708-713 (1997).
37. Despres, J. P. et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334, 952-957 (1996).
38. Ren, J. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinol 181, 1-10 (2004).
39. Ebbert, J. O. & Jensen, M. D. Fat depots, free fatty acids, and dyslipidemia. Nutrients 5, 498-508 (2013).
40. Nedergaard, J. & Cannon, B. The Browning of White Adipose Tissue: Some Burning Issues. Cell Metab 20, 396-407 (2014).
41. Okuno, A. et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101, 1354-1361 (1998).
42. Deeb, S. S. et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20, 284-287 (1998).
43. Kadowaki, T. et al. The role of PPARgamma in high-fat diet-induced obesity and insulin resistance. J Diabetes Complications 16, 41-45 (2002).
44. Bedoucha, M., Atzpodien, E. & Boelsterli, U. A. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 35, 17-23 (2001).
45. Watkins, S. M., Reifsnyder, P. R., Pan, H. J., German, J. B. & Leiter, E. H. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 43, 1809-1817 (2002).
46. Hummon, A. B., Lim, S. R., Difilippantonio, M. J. & Ried, T. Isolation and solubilization of proteins after TRIzol extraction of RNA and DNA from patient material following prolonged storage. Biotechniques 42, 467-470, 472 (2007).
47. Chang, Y. Prusoff, W. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibitions (I50) of on enzymatic reaction. Biochem Pharmacol 22, 3099-3108 (1973).